Beijing Key Laboratory for Innovative Diagnosis and Treatment of Neurological Rare Diseases Approved, Jointly Established by Peking University Third Hospital and Anlong Bio

Beijing News: According to the Shunyi District Media Convergence Center, Shunyi District has achieved another landmark success in the collaborative innovation of industry, academia, and research for rare diseases, as well as in the quality improvement and upgrading of the pharmaceutical and health industries. The “Beijing Key Laboratory for Innovative Diagnosis, Treatment, and Translation of Neurological Rare Diseases,” jointly established by Peking University Third Hospital (hereinafter referred to as “PUH3”) and Beijing Anlong Biopharmaceutical Co., Ltd., an enterprise in the Capital Airport临空Economic Zone, has been approved. The laboratory will integrate the entire chain of “clinical diagnosis and treatment – basic scientific research – new drug development – mass production and implementation,” addressing industrial shortcomings such as the shortage of domestically developed original drugs for rare diseases and the slow translation of scientific research achievements in China.

Peking University Third Hospital is a benchmark for the diagnosis and treatment of rare neurological diseases in China, boasting a leading nationwide cohort of patients with rare diseases, a full-cycle follow-up database, and clinical sample resources. This enables precise alignment with the real-world diagnostic and therapeutic needs of patients in China, thereby clarifying directions for new drug development. Anlong, a specialized, refined, distinctive, and innovative high-tech enterprise in Shunyi District, is deeply engaged in the fields of AAV (adeno-associated virus) gene therapy and small nucleic acid innovative drugs. Leveraging its core R&D platform with independent intellectual property rights, the company is steadily advancing the clinical trials of multiple new drugs under development for rare diseases.

By joining forces, the two parties will precisely address the diagnostic and therapeutic challenges of high-prevalence rare neurological diseases, such as amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth disease. They will introduce top-tier clinical medical resources into the fertile industrial ground of the Capital Airport Economic Zone, enabling local translation of clinical needs and nearby implementation of innovative drugs, thereby maximizing the synergistic efficiency of industry, academia, and research. Moving forward, Anlong and Peking University Third Hospital will continue to deepen their efforts in developing original therapies for rare neurological diseases, accelerate the development and implementation of gene therapies and small nucleic acid drugs currently under investigation, leverage the advantages of the pilot zone to promote the rapid entry of innovative drugs into domestic clinical applications, and effectively alleviate the plight of rare disease patients facing a shortage of medical care and medications.

The Capital Airport Aviation Economic Zone is accelerating the construction of China’s only pilot zone for rare disease drug security. It has established a full-chain rare disease industry system encompassing “R&D incubation–bonded warehousing–cross-border import–clinical application.” Leveraging district-level special support policies for pharmaceuticals and healthcare, empowerment by the aviation industry fund, and supporting infrastructure from the Airport Biopharmaceutical Industrial Park, the zone continues to attract the agglomeration and development of top-tier medical institutions, innovative pharmaceutical companies, and scientific research platforms.

“We will continue to leverage the policies of the pilot zone, deepen strategic cooperation with top-tier medical institutions across China such as Peking University Third Hospital and Beijing Friendship Hospital, accelerate the introduction of high-quality sci-tech innovation projects and leading biomedical enterprises, and build a nationally leading hub for innovative diagnosis, treatment, and achievement transformation in rare diseases, thereby empowering high-quality regional industrial development with new quality productive forces in life and health,” said a relevant official from the Management Committee of the Capital Airport Economic Zone.

Editor: Zhang Qian